keyword
https://read.qxmd.com/read/38131058/efficacy-and-safety-of-pharmacotherapy-in-chronic-insomnia-a-review-of-clinical-guidelines-and-case-reports
#21
REVIEW
Alejandro Del Rio Verduzco, Ahva Salari, Parna Haghparast
INTRODUCTION: Chronic insomnia affects 5% to 10% of the US population, increasing the demand for treatment options and the corresponding research to prove their validity.1 This review compares recommendations from 3 clinical guidelines and summarizes hypnotic medications, including their newly reported side effects not mentioned in the guidelines. In addition, we aim to provide an overview of what pharmacotherapies are available for prescribers and patients. METHODS: A literature search was conducted for articles published prior to January 10, 2022, and case reports and clinical studies were retrieved from PubMed and Google Scholar...
October 2023: Mental Health Clinician
https://read.qxmd.com/read/38063235/a-retrospective-clinical-practice-study-comparing-the-usefulness-of-dual-orexin-receptor-antagonists-and-a-melatonin-receptor-agonist-in-patients-switching-from-long-term-benzodiazepine-receptor-agonists
#22
JOURNAL ARTICLE
Masumi Tachibana, Nobuhisa Kanahara, Yasunori Oda, Tadashi Hasegawa, Atsushi Kimura, Masaomi Iyo
STUDY OBJECTIVES: Although novel hypnotics have recently emerged, there are currently no data comparing the clinical potency of benzodiazepine receptor agonists (BZRAs) and novel hypnotics, or the effectiveness of different methods of switching between them. This study examined how novel hypnotics might help reduce BZRA use in real-world practice. METHODS: 289 patients with psychiatric disorders who took BZRAs for over 1 year before switching to either of two dual-orexin receptor antagonists (DORAs) (suvorexant (SUV) or lemborexant (LEM)) or a melatonin receptor agonist (ramelteon (RMT)) were enrolled...
December 8, 2023: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
https://read.qxmd.com/read/38059250/guidelines-for-pharmacotherapy-in-alzheimer-s-disease-a-primer-on-fda-approved-drugs
#23
REVIEW
Ashvin Varadharajan, Aarjith Damian Davis, Aishwarya Ghosh, Tejaswini Jagtap, Anjo Xavier, Anjana Jayakumar Menon, Dwaiti Roy, Sandhya Gandhi, Thomas Gregor
The growing prevalence of dementia makes it important for us to better understand its pathophysiology and treatment modalities, to improve the quality of life of patients and caregivers. Alzheimer's disease (AD), a neurodegenerative disease, is the most common form of amnestic dementia in the geriatric population. Pathophysiology of AD is widely attributed to aggregation of amyloid-beta (Aβ) plaques and hyperphosphorylation of tau proteins. Initial treatment modalities aimed to increase brain perfusion in a non-specific manner...
2023: Journal of Neurosciences in Rural Practice
https://read.qxmd.com/read/38037168/efficacy-of-combined-use-of-suvorexant-and-ramelteon-in-preventing-postoperative-delirium-a-retrospective-comparative-study
#24
JOURNAL ARTICLE
Shoya Ikeuchi, Rei Tanaka, Teiichi Sugiura, Kaori Shinsato, Akane Wakabayashi, Junya Sato, Keiko Suzuki, Michihiro Shino
BACKGROUND: Suvorexant and ramelteon have been presented as useful for preventing postoperative delirium. Previous studies reported on the comparison with benzodiazepine hypnotics which have been known for the risk for inducing delirium, but the comparison with patients not taking any hypnotics has not been reported yet. Therefore, we assessed the incidence rates for postoperative delirium comparing cancer patients who received preoperative combined administration with suvorexant and ramelteon and those not taking any hypnotics...
December 1, 2023: Journal of Pharmaceutical Health Care and Sciences
https://read.qxmd.com/read/38029810/sleep-loss-caffeine-sleep-aids-and-sedation-modify-brain-abnormalities-of-mild-traumatic-brain-injury
#25
JOURNAL ARTICLE
Carol A Everson, Aniko Szabo, Cade Plyer, Thomas A Hammeke, Brian D Stemper, Mathew D Budde
Little evidence exists about how mild traumatic brain injury (mTBI) is affected by commonly encountered exposures of sleep loss, sleep aids, and caffeine that might be potential therapeutic opportunities. In addition, while propofol sedation is administered in severe TBI, its potential utility in mild TBI is unclear. Each of these exposures is known to have pronounced effects on cerebral metabolism and blood flow and neurochemistry. We hypothesized that they each interact with cerebral metabolic dynamics post-injury and change the subclinical characteristics of mTBI...
November 28, 2023: Experimental Neurology
https://read.qxmd.com/read/37982383/failure-of-the-dual-orexin-receptor-antagonist-suvorexant-to-engender-drug-discrimination-in-rats
#26
JOURNAL ARTICLE
Michel A Steiner, Michael Toeroek-Schafroth, Lisa Dacome, Michela Tessari
For abuse potential assessment, U.S. Food and Drug Administration (FDA) requests that new, brain-penetrating drugs are ideally compared with approved drugs that share the mechanism of action and are judged to have abuse liability by the Drug Enforcement Agency. For development of the dual orexin receptor antagonist (DORA) daridorexant, the FDA recommended conducting a rat drug discrimination paradigm against the approved, schedule IV, DORA suvorexant. Surprisingly, at suvorexant plasma levels up to three-fold the maximum concentration at the highest approved human dose, rats did not learn to discriminate the suvorexant stimulus from vehicle...
November 20, 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/37950346/clinical-safety-and-narcolepsy-like-symptoms-of-dual-orexin-receptor-antagonists-in-patients-with-insomnia-a-systematic-review-and-meta-analysis
#27
JOURNAL ARTICLE
Hyun-Jin Na, Nakyung Jeon, Christine E Staatz, Nayoung Han, In-Hwan Baek
STUDY OBJECTIVES: Dual orexin receptor antagonists (DORAs) are emerging treatments for insomnia. This meta-analysis study aimed to assess the safety of FDA-approved DORAs (suvorexant, lemborexant, and daridorexant), focusing on narcolepsy-like symptoms associated with these drugs. METHODS: Five prominent databases were searched to identify randomized controlled trials (RCTs) on this topic. Primary safety outcomes included treatment-emergent adverse events (TEAEs), treatment-related TEAEs, TEAEs leading to discontinuation, and serious TEAEs...
February 8, 2024: Sleep
https://read.qxmd.com/read/37946602/trends-in-the-multiple-prescriptions-of-hypnotic-drugs-in-a-university-outpatient-in-japan
#28
JOURNAL ARTICLE
Takao Kato, Nozomu Kotorii, Motohiro Ozone, Kenta Murotani, Hayato Ohshima, Hiroyuki Mori, Kenjirou Wasano, Hiroshi Hiejima, Mitsunari Habukawa, Naohisa Uchimura
AIMS: In Japan, the daily dosage of hypnotic drugs for insomnia treatment is increasing year by year, and over-dependence on treatment with hypnotic drugs is a major problem. This study aimed to examine the factors related to the elimination of prescriptions of three or more hypnotic drugs within 1 year in our clinic. METHODS: We conducted two surveys. Survey ① assessed the frequency of prescriptions of three or more hypnotic drugs by retrospectively reviewing the medical records of all patients who visited general and psychiatric outpatient clinics from January 2013 to March 2019...
November 9, 2023: Neuropsychopharmacology Reports
https://read.qxmd.com/read/37931704/the-effects-of-a-dual-orexin-receptor-antagonist-on-fear-extinction-memory-and-sleep-in-mice-implications-for-exposure-therapy
#29
JOURNAL ARTICLE
Ihori Kobayashi, Patrick A Forcelli
Extinction of conditioned fear is considered a fundamental process in the recovery from posttraumatic stress disorder and anxiety disorders. Sleep, especially rapid-eye-movement (REM) sleep, has been implicated in promoting extinction memory. The orexin system contributes to the regulation of sleep and wakefulness and emotional behaviors. In rodents, administrations of an orexin receptor antagonist following fear extinction training enhanced consolidation of extinction memory. Although orexin antagonists increase sleep, including REM sleep, the possible contribution of sleep to the effects of orexin antagonists on extinction memory has not been examined...
November 4, 2023: Behavioural Brain Research
https://read.qxmd.com/read/37901579/quantification-of-suvorexant-in-human-urine-using-a-validated-hptlc-bioanalytical-method
#30
JOURNAL ARTICLE
Mohammed H Alqarni, Muzaffar Iqbal, Ahmed I Foudah, Tariq M Aljarba, Fatma Abdel Bar, Sultan Alshehri, Faiyaz Shakeel, Prawez Alam
Suvorexant (SUV) is a new sedative/hypnotic medicine that is recommended to treat insomnia. It is an important medicine from a forensic point of view due to its sedative/hypnotic and depressant effects. To the best of our knowledge, high-performance thin-layer chromatography (HPTLC) bioanalytical methods have not been published to measure SUV in human urine and pharmaceutical samples. Accordingly, this study was designed and validated a sensitive and rapid bioanalytical HPTLC method to determine SUV in human urine samples for the very first time...
October 24, 2023: ACS Omega
https://read.qxmd.com/read/37882457/reducing-the-use-of-psychotropics-in-a-convalescent-rehabilitation-ward
#31
JOURNAL ARTICLE
Takuya Uematsu, Takashi Tomita, Ryo Obara, Takuya Gonai, Koshi Hattori, Takanori Aonuma, Kensuke Usui, Hiroaki Tanifuji, Fumiaki Ishizawa, Hiroshi Ishii, Eiji Suzuki
AIMS: Many patients who are transferred to the convalescent rehabilitation ward of Kawasaki Kokoro Hospital (hereinafter, our hospital) are on psychotropics prescribed for delirium by their physicians at acute care hospitals. In this study, psychiatrists and pharmacists collaborated with rehabilitation physicians to reduce the use of psychotropics. METHODS: The basic information and psychotropics prescription statuses of 88 patients discharged from the convalescent rehabilitation ward of our hospital between April 1, 2021 and March 31, 2022 were derived from their medical records...
October 26, 2023: Neuropsychopharmacology Reports
https://read.qxmd.com/read/37824500/effect-of-pharmacist-led-intervention-protocol-on-preventing-postoperative-delirium-after-elective-cardiovascular-surgery
#32
JOURNAL ARTICLE
Yuki Asai, Tatsuki Yanagawa, Masaaki Takahashi
Postoperative delirium (PD) is an acute brain dysfunction, with a particularly high incidence after cardiovascular surgery. Pharmacist-led interventions show limited evidence in attenuating PD in cardiovascular surgery. In this retrospective cohort study, we aimed to clarify the risk factors of PD for cardiovascular surgery focused on pharmacotherapy and elucidate the effect of pharmacist-led intervention on the PD attenuation rate based on protocol-based pharmaceutical management (PBPM). This study included 142 adult patients who underwent elective valve replacement or valvuloplasty...
2023: PloS One
https://read.qxmd.com/read/37811652/using-pharmacotherapy-to-address-sleep-disturbances-in-autism-spectrum-disorders
#33
REVIEW
Valeria Mammarella, Silvia Orecchio, Noemi Cameli, Sara Occhipinti, Lavinia Marcucci, Giuliano De Meo, Alice Innocenti, Raffaele Ferri, Oliviero Bruni
INTRODUCTION: Sleep disorders are the second most common medical comorbidity in autism spectrum disorder (ASD), with effects on daytime behavior and functioning, mood and anxiety, and autism core features. In children with ASD, insomnia also has a negative impact on the whole family's quality of life. Therefore, treatment of sleep disturbances should be considered as a primary goal in the management of ASD patients, and it is important to clarify the scientific evidence to inappropriate treatments...
2023: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/37790550/prediction-of-adverse-events-risk-in-patients-with-comorbid-post-traumatic-stress-disorder-and-alcohol-use-disorder-using-electronic-medical-records-by-deep-learning-models
#34
Oshin Miranda, Peihao Fan, Xiguang Qi, Haohan Wang, M Daniel Brannock, Thomas Kosten, Neal David Ryan, Levent Kirisci, LiRong Wang
Background Prediction of high-risk events in mental disorder patients is crucial. In our previous study, we developed a deep learning model: DeepBiomarker by using electronic medical records (EMR) to predict suicide related event (SRE) risk in post-traumatic stress disorder (PTSD) patients. Methods We applied DeepBiomarker2 through data integration of multimodal information: lab test, medication, co-morbidities, and social determinants of health. We analyzed EMRs of 5,565 patients from University of Pittsburgh Medical Center with a diagnosis of PTSD and alcohol use disorder (AUD) on risk of developing an adverse event (opioid use disorder, SREs, depression and death)...
September 18, 2023: Research Square
https://read.qxmd.com/read/37790444/opiate-anticipation-opiate-induced-anatomical-changes-in-hypocretin-hcrt-orexin-neurons-and-opiate-induced-microglial-activation-are-blocked-by-the-dual-hcrt-receptor-antagonist-suvorexant-while-opiate-analgesia-is-maintained
#35
Ronald McGregor, Ming-Fung Wu, Thomas C Thannickal, Jerome M Siegel
We previously found that heroin addiction in humans is accompanied by an increase in the number of detected Hcrt neurons and a decrease in their soma size. We now show that the increased number of Hcrt cells visible after morphine treatment is likely the result of increased Hcrt production in neurons having sub-detection levels of the peptides. We find that morphine increases Hcrt projections to the ventral tegmental area (VTA), the level of tyrosine hydroxylase enzyme (TH) and the number of TH positive cells in VTA, with no changes in the adjacent substantia nigra...
September 23, 2023: bioRxiv
https://read.qxmd.com/read/37596710/effect-of-lemborexant-on-pharmacokinetics-of-clozapine-a-potential-drug-drug-interaction-mediated-by-time-dependent-inhibition-of-cyp3a4
#36
JOURNAL ARTICLE
Kenya Watanabe, Shingen Misaka, Keiko Kanno-Nozaki, Takaaki Chiyoda, Yuhei Suzuki, Akiko Sato, Takahiro Suto, Junko Kuroda, Kenju Shimomura, Itaru Miura, Hirooki Yabe
Clozapine (CLZ) is extensively used for treatment-resistant schizophrenia (TRS) with caution to avoid serious adverse events such as agranulocytosis and drug-drug interactions (DDIs). In the current report, we present a case of a 35-year-old male non-smoking TRS patient whose steady-state plasma trough concentrations (Ctrough ) of CLZ and its active metabolite, N-desmethylclozapine (NDMC), were significantly increased after initiating oral administration of lemborexant (LEM), a dual orexin receptor antagonist, for the treatment of insomnia...
August 18, 2023: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/37561254/ramelteon-and-suvorexant-for-postoperative-delirium-in-elderly-patients-with-esophageal-cancer
#37
JOURNAL ARTICLE
Shuhei Mayanagi, Ryoma Haneda, Masazumi Inoue, Kenjiro Ishii, Yasuhiro Tsubosa
BACKGROUND: There is no clear evidence on the prevention of postoperative delirium with pharmacotherapy in elderly patients with esophageal cancer. This retrospective study aimed to evaluate the efficacy of ramelteon and suvorexant in preventing postoperative delirium in this patient group. METHODS: Data on 251 patients who received radical esophagectomy for thoracic esophageal cancer were collected from January 2010 to September 2021. In total, 74 patients did not receive preventive intervention, and 177 received ramelteon and suvorexant...
August 10, 2023: Esophagus: Official Journal of the Japan Esophageal Society
https://read.qxmd.com/read/37553894/orexin-2-receptor-antagonism-sex-dependently-improves-sleep-wakefulness-and-cognitive-performance-in-tau-transgenic-mice
#38
JOURNAL ARTICLE
Ryan J Keenan, Heather Daykin, Jeremy Metha, Linda Cornthwaite-Duncan, David K Wright, Kyra Clarke, Sara Oberrauch, Maddison Brian, Sarah Stephenson, Cameron J Nowell, Giancarlo Allocca, Kevin J Barnham, Daniel Hoyer, Laura H Jacobson
BACKGROUND AND PURPOSE: Tau pathology contributes to a bidirectional relationship between sleep disruption and neurodegenerative disease. Tau transgenic rTg4510 mice model tauopathy symptoms including sleep/wake disturbances, which manifest as marked hyperarousal. This phenotype can be prevented by early transgene suppression, however, whether hyperarousal can be rescued after its onset is unknown. EXPERIMENTAL APPROACH: Three chronic (8-week) experiments were conducted with wild-type and rTg4510 mice after the age of onset of hyperarousal (4...
August 8, 2023: British Journal of Pharmacology
https://read.qxmd.com/read/37549414/insomnia-management-a-review-and-update
#39
REVIEW
David P Shaha
Insomnia is a distinct disorder that is common, yet underrecognized and undertreated in primary care. Treating insomnia has been shown to improve outcomes, including reduced risk of developing cardiovascular and mental health disorders. Insomnia is influenced by the brain's regulation of sleep and wake, which are mutually exclusive events. Insomnia should be treated as a distinct condition, even when occurring with a comorbid diagnosis such as depression or anxiety. Clinicians should implement a multimodal approach to insomnia management, including nonpharmacologic interventions and pharmacologic therapy (when indicated)...
July 2023: Journal of Family Practice
https://read.qxmd.com/read/37532564/effects-of-blindness-on-sleep-wakefulness-states-in-mice
#40
JOURNAL ARTICLE
Yoshinori Iba, Shota En, Yukika Yamada, Mayu Koami, Nagisa Yamamoto, Shinichi Sawada, Naono Yamawaki
To examine the effects of blindness on sleep/wakefulness states, we compared locomotor activity and delayed recovery from isoflurane anesthesia induced by hypnotics during light and dark periods in sighted CBA/N and blind CBA/J mice. Locomotor activity around the switch from the dark to light period significantly differed in both mice. Delayed recovery induced by brotizolam was attenuated in both periods in CBA/J mice. In addition, the period specificity of delayed recovery caused by suvorexant or diphenhydramine in CBA/N mice was abolished in CBA/J mice...
2023: Biological & Pharmaceutical Bulletin
keyword
keyword
37227
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.